E. Derom (Gent, Belgium), G. Brusselle (Ghent, Belgium), N. Barnes (London, United Kingdom), R. Singh (Hampstead, United Kingdom)
Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea
D. Mahler, R. Buhl, D. Lawrence, D. McBryan (Lebanon, United States Of America; Mainz, Germany; Horsham, United Kingdom; Basel, Switzerland)
|   |
Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies
D. Banerji, V. Alagappan, C. Martin, E. He, H. Chen, T. Overend (East Hanover, United States Of America; Horsham, United Kingdom)
| |
Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial
M. Sekiya, T. Kawayama, Y. Fukuchi, Y. Takahashi, T. Kaiso, K. Ikeda, T. Overend, D. Banerji (Tokyo, Fukuoka, Japan; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Sputum neutrophil monitoring is useful for long-term oxygen therapy in patients with COPD
M. Miyamoto, K. Takao, Y. Okada, M. Maruyama, E. Tsurugai, Y. Nakazato, M. Adachi (Ohta City, Japan)
| |
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial
H.N. Tse, K.Y. Wong, K.S. Yee, L.Y. Ng (Hong Kong, Hong Kong)
| |
Cost-effectiveness of adding budesonide/formoterol to tiotropium in severe COPD patients in four Nordic countries
R. Nielsen, H. Kankaanranta, L. Bjermer, P. Lange, S. Arnetorp, M. Hedegaard, A. Stenling, N. Mittmann (Bergen, Norway; Seinäjoki, Finland; Lund, Mölndal, Södertälje, Sweden; Copenhagen, Hvidovre, Denmark)
| |
Effect of once-daily indacaterol in a predominantly Chinese COPD population: A 26-week Asia-Pacific study
W. Yao, C. Wang, N. Zhong, W. Yang, M. Henley, B. Kramer (Beijing, Chongqing, Guangzhou, China; East Hanover, United States Of America; Horsham, United Kingdom)
| |
Budesonide/formoterol vs formoterol, both via Turbuhaler®, in patients with moderate to severe COPD: Phase III study results
M. Ichinose, R. Samoro, R. Fassakhov, M. Oguri, J. Ekelund, L.G. Carlsson, Y. Fukuchi (Wakayama, Hokkaido, Tokyo, Japan; Iloilo City, Philippines; Kazan, Russian Federation; Molndal, Sweden)
| |
Effect of roflumilast on hospitalizations in COPD patients
E. Bateman, J. Jardim, U.M. Goehring, M. Brose, P. Calverley (Cape Town, South Africa; Sao Paulo, Brazil; Konstanz, Germany; Liverpool, United Kingdom)
| |
The effect of tiotropium on lung dynamic hyperinflation and treadmill exercise capacity in mild to moderate COPD
R. Casaburi, F. Maltais, J. Porszasz, F. Albers, Q. Deng, A. Iqbal, H. Paden, D. O‘Donnell (Torrance, Ridgefield, New York, United States Of America; Quebec, Kingston, Canada)
| |
Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD
H. Ohbayashi, M. Adachi (Mizunami, Tokyo, Japan)
| |
The impact of treatment of chronic obstructive pulmonary disease (COPD) on functional status and quality of life of patients
D. Tsavlis, M. Theodorou, A. Tzoumaka, H. Lithoxopoulou, P. Minogiannis, V. Tsaousis, A. Tektonidou, D. Kaitelidou (Thessaloniki, Greece; Nicosia, Cyprus; New York, United States Of America)
| |
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations
P.M.A. Calverley, M.T. Dransfield, J. Bourbeau, P. Jones, N.A. Hanania, D.A. Mahler, J. Vestbo, A. Wachtel, F. Martinez, F. Barnhart, L. Sanford, S. Lettis, C. Crim (Liverpool, London, Manchester, Uxbridge, United Kingdom; Houston, Hanover, Los Angeles, Ann Arbor, Research Triangle Park, United States Of America; Montreal, Canada)
| |
Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination can decrease mortality of COPD patients, a nationwide population-based cohort study in Taiwan
M.C. Chan, G.H. Lin (Taichung, Taiwan)
| |
Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs
A. Gavaldà, M. Vinyals, J. Aubets, J. Gras (Barcelona, Spain)
| |
Risk of pneumonia related to budesonide use in COPD: An updated pooled analysis
D. Sin, D. Tashkin, F. Radner, U. Sjobring, A. Thoren, P. Calverley, S. Rennard (Vancouver, Canada; Los Angeles, Omaha, United States Of America; Molndal, Sweden; Liverpool, United Kingdom)
| |
Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study
A. Gelb, D. Tashkin, B. Make, X. Zhong, E. Garcia Gil, C. Caracta (Lakewood, Los Angeles, Denver, Jersey City, United States Of America; Barcelona, Spain)
| |
Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency
I. Ferrarotti, T.P. Carroll, S. Inghilleri, S. Ottaviani, M. Luisetti, N.G. McElvaney (Pavia, Italy; Dublin, Ireland)
| |
NFAT subtypes in regulating Th2 lymphocytes
X. Yao, Y. Teng, H. Huang, I. Adcock, P. Barnes (Nanjing, China; London, United Kingdom)
| |